BRCC36 and Telomerase Levels in Women With Polycystic Ovary Syndrome

NCT07849166 | Completed

• 1 other identifier: PCOS-Dubs-TE
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational case-control study evaluated serum BRCC36 and telomerase (TE) levels in women with polycystic ovary syndrome (PCOS) and healthy controls. Women aged 18-43 years were included. The study comprised 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles. A single 5-mL venous blood sample was collected from each participant. Serum was separated by centrifugation and stored at -80°C until analysis. Serum BRCC36 and telomerase levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits. The study evaluated differences in these biomarkers between women with PCOS and healthy controls and their relationships with clinical and biochemical characteristics.

Conditions

Polycystic Ovarian Syndrome (PCOS)

Keywords

BRCC36; Telomerase; Deubiquitinating Enzymes; Polycystic Ovary Syndrome; Biomarkers

Outcome Measures

Primary Outcomes (2)

• Serum BRCC36 Level

  Serum BRCC36 levels measured using a commercially available human ELISA kit and compared between the PCOS and healthy control groups.

  At study enrollment (single blood collection)

• Serum Telomerase Level

  Serum telomerase (TE) levels measured using a commercially available human ELISA kit and compared between the PCOS and healthy control groups.

  At study enrollment (single blood collection)

Study Arms (2)

PCOS Group

Women aged 18-43 years diagnosed with polycystic ovary syndrome according to ESHRE/ASRM criteria (n=30).

Healthy Control Group

Healthy women aged 18-43 years with regular menstrual cycles and without clinical or ultrasonographic features of PCOS (n=30).

Eligibility Criteria

• Age: 18 Years - 43 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Women aged 18-43 years attending Sivas Cumhuriyet University Faculty of Medicine Hospital were included. The study population consisted of 30 women diagnosed with PCOS according to ESHRE/ASRM criteria and 30 healthy women with regular menstrual cycles who served as controls. All participants were non-obese (BMI \<30 kg/m²) and provided written informed consent.

You may qualify if:

• Women aged 18-43 years.
• PCOS group: diagnosis of PCOS according to ESHRE/ASRM criteria, based on the presence of at least two of the following: oligo- and/or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology.
• Control group: healthy women with regular menstrual cycles (21-35 days), modified Ferriman-Gallwey score \<8, and no unilateral or bilateral polycystic ovarian morphology on pelvic ultrasonography.
• BMI \<30 kg/m².
• No oral contraceptive use during the study period or within the previous 6 months.
• Written informed consent.

You may not qualify if:

• Thyroid dysfunction, prolactinoma, Cushing disease, or late-onset congenital adrenal hyperplasia.
• Diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, or renal or hepatic dysfunction.
• Additional gynecological disease.
• Use of medications affecting sex hormone or carbohydrate metabolism.
• Inadequate or unsuitable blood/serum sample for laboratory analysis.

Sponsors & Collaborators

• Cumhuriyet University: lead

Study Sites (1)

Sivas Cumhuriyet University

Sivas, Sivas, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum samples collected from venous blood and stored at -80°C for BRCC36 and telomerase (TE) measurements by ELISA.

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Study Officials

• Dilara Ülger Özbek, PhD

  Cumhuriyet University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Asistant Professor

Study Record Dates

• First Submitted: September 24, 2026
• First Posted: September 30, 2026
• Study Start: February 20, 2024
• Primary Completion: February 20, 2025
• Study Completion: May 1, 2026
• Last Updated: September 30, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)